| Basics |
Corbus Pharmaceuticals Holdings, Inc. Common Stock
Corbus Pharmaceuticals Holdings Inc is a Phase 3 clinical-stage pharmaceutical company focused on the development and commercialization of novel therapeutics to treat rare, chronic, and serious inflammatory and fibrotic diseases.
|
| IPO Date: |
November 1, 2014 |
| Sector: |
Healthcare |
| Industry: |
Biotech |
| Market Cap: |
$179.74M |
| Activated in VL: |
True |
| Average Daily Range |
| Avg Daily Range: |
$0.32 | 3.88%
|
| Avg Daily Range (30 D): |
$0.36 | 3.02%
|
| Avg Daily Range (90 D): |
$0.41 | 3.32%
|
| Institutional Daily Volume |
| Avg Daily Volume: |
1.25M |
| Avg Daily Volume (30 D): |
.39M |
| Avg Daily Volume (90 D): |
.25M |
| Trade Size |
| Avg Trade Size (Sh.): |
247 |
| Avg Trade Size (Sh.) (30 D): |
71 |
| Avg Trade Size (Sh.) (90 D): |
68 |
| Institutional Trades |
| Total Inst.Trades: |
445 |
| Avg Inst. Trade: |
$1.76M |
| Avg Inst. Trade (30 D): |
$.88M |
| Avg Inst. Trade (90 D): |
$.93M |
| Avg Inst. Trade Volume: |
.04M |
| Avg Inst. Trades (Per Day): |
1 |
| Market Closing Trades |
| Avg Closing Trade: |
$2.06M |
| Avg Closing Trade (30 D): |
$.74M |
| Avg Closing Trade (90 D): |
$1.05M |
| Avg Closing Volume: |
44.72K |
|
|
| Financials |
| |
TTM |
Q3 2025 |
Q2 2025 |
|
Basic EPS
|
$-5.49
|
$-1.9
|
$-1.44
|
|
Diluted EPS
|
$-5.49
|
$-1.9
|
$-1.44
|
|
Revenue
|
$ 5.9M
|
$ 1.13M
|
$ 1.31M
|
|
Gross Profit
|
$
|
$
|
$
|
|
Net Income / Loss
|
$ -67.51M
|
$ -23.34M
|
$ -17.66M
|
|
Operating Income / Loss
|
$ -75.95M
|
$ -24.42M
|
$ -19.15M
|
|
Cost of Revenue
|
$
|
$
|
$
|
|
Net Cash Flow
|
$ 7.56M
|
$ 9.79M
|
$ M
|
|
PE Ratio
|
|
|
|
| Splits |
|
Feb 14, 2023:
1:30
|
|
|
|
